Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

The vertebrate tail: a gene playground for evolution.

Mallo M.

Cell Mol Life Sci. 2019 Sep 26. doi: 10.1007/s00018-019-03311-1. [Epub ahead of print] Review.

PMID:
31559446
2.

Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.

Ganster C, Müller-Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, Hildebrandt B, Mallo M, Lübbert M, Müller C, Solé F, Götze KS, Vandenberghe P, Göhring G, Steinmetz T, Kröger N, Platzbecker U, Söling U, Raynaud S, Shirneshan K, Schanz J, Haase D.

Genes Chromosomes Cancer. 2019 Oct;58(10):689-697. doi: 10.1002/gcc.22760. Epub 2019 Apr 30.

PMID:
30994215
3.

Tail Bud Progenitor Activity Relies on a Network Comprising Gdf11, Lin28, and Hox13 Genes.

Aires R, de Lemos L, Nóvoa A, Jurberg AD, Mascrez B, Duboule D, Mallo M.

Dev Cell. 2019 Feb 11;48(3):383-395.e8. doi: 10.1016/j.devcel.2018.12.004. Epub 2019 Jan 17.

PMID:
30661984
4.

The effect of stopping phenprocoumon 5 days preoperatively: A retrospective study.

Knol S, Mallo M, Tromp Meesters R, Westerink J, van de Ree M.

Res Pract Thromb Haemost. 2018 Nov 9;3(1):85-88. doi: 10.1002/rth2.12159. eCollection 2019 Jan.

5.

Regulatory landscape of the Hox transcriptome.

Casaca A, Hauswirth GM, Bildsoe H, Mallo M, McGlinn E.

Int J Dev Biol. 2018;62(11-12):693-704. doi: 10.1387/ijdb.180270em. Review.

PMID:
30604839
6.

Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance.

Schanz J, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D.

Genes Chromosomes Cancer. 2018 Nov;57(11):547-556. doi: 10.1002/gcc.22667. Epub 2018 Sep 24.

PMID:
30248204
7.

Deconstructing the molecular mechanisms shaping the vertebrate body plan.

Aires R, Dias A, Mallo M.

Curr Opin Cell Biol. 2018 Dec;55:81-86. doi: 10.1016/j.ceb.2018.05.009. Epub 2018 Jul 14. Review.

PMID:
30015151
8.

Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes.

Martin R, Acha P, Ganster C, Palomo L, Dierks S, Fuster-Tormo F, Mallo M, Ademà V, Gómez-Marzo P, De Haro N, Solanes N, Zamora L, Xicoy B, Shirneshan K, Flach J, Braulke F, Schanz J, Kominowski A, Stromburg M, Brockmann A, Trümper L, Solé F, Haase D.

Am J Hematol. 2018 Jun;93(6):E152-E154. doi: 10.1002/ajh.25089. Epub 2018 Apr 10. No abstract available.

9.

Reassessing the Role of Hox Genes during Vertebrate Development and Evolution.

Mallo M.

Trends Genet. 2018 Mar;34(3):209-217. doi: 10.1016/j.tig.2017.11.007. Review.

PMID:
29269261
10.

A tissue-specific, Gata6-driven transcriptional program instructs remodeling of the mature arterial tree.

Losa M, Latorre V, Andrabi M, Ladam F, Sagerström C, Novoa A, Zarrineh P, Bridoux L, Hanley NA, Mallo M, Bobola N.

Elife. 2017 Sep 27;6. pii: e31362. doi: 10.7554/eLife.31362.

11.

Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms.

Ribera J, Zamora L, Morgades M, Mallo M, Solanes N, Batlle M, Vives S, Granada I, Juncà J, Malinverni R, Genescà E, Guàrdia R, Mercadal S, Escoda L, Martinez-Lopez J, Tormo M, Esteve J, Pratcorona M, Martinez-Losada C, Solé F, Feliu E, Ribera JM; Spanish PETHEMA Group and the Spanish Society of Hematology.

Genes Chromosomes Cancer. 2017 Nov;56(11):810-820. doi: 10.1002/gcc.22486. Epub 2017 Aug 26.

PMID:
28758283
12.

Inspecting Targeted Deep Sequencing of Whole Genome Amplified DNA Versus Fresh DNA for Somatic Mutation Detection: A Genetic Study in Myelodysplastic Syndrome Patients.

Palomo L, Fuster-Tormo F, Alvira D, Ademà V, Armengol MP, Gómez-Marzo P, de Haro N, Mallo M, Xicoy B, Zamora L, Solé F.

Biopreserv Biobank. 2017 Aug;15(4):360-365. doi: 10.1089/bio.2016.0094. Epub 2017 Jun 6.

PMID:
28586236
13.

A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples.

Esteve-Codina A, Arpi O, Martinez-García M, Pineda E, Mallo M, Gut M, Carrato C, Rovira A, Lopez R, Tortosa A, Dabad M, Del Barco S, Heath S, Bagué S, Ribalta T, Alameda F, de la Iglesia N, Balaña C; GLIOCAT Group.

PLoS One. 2017 Jan 25;12(1):e0170632. doi: 10.1371/journal.pone.0170632. eCollection 2017.

14.

Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.

Drusbosky L, Medina C, Martuscello R, Hawkins KE, Chang M, Lamba JK, Vali S, Kumar A, Singh NK, Abbasi T, Sekeres MA, Mallo M, Sole F, Bejar R, Cogle CR.

Leuk Res. 2017 Jan;52:1-7. doi: 10.1016/j.leukres.2016.11.004. Epub 2016 Nov 6.

15.

Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia.

Palau A, Mallo M, Palomo L, Rodríguez-Hernández I, Diesch J, Campos D, Granada I, Juncà J, Drexler HG, Solé F, Buschbeck M.

Genes Chromosomes Cancer. 2017 Mar;56(3):243-252. doi: 10.1002/gcc.22430. Epub 2016 Nov 21.

PMID:
27750403
16.

Local indicators of climate change: The potential contribution of local knowledge to climate research.

Reyes-García V, Fernández-Llamazares Á, Guèze M, Garcés A, Mallo M, Vila-Gómez M, Vilaseca M.

Wiley Interdiscip Rev Clim Change. 2016 Jan;7(1):109-124.

17.

Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.

Palomo L, Garcia O, Arnan M, Xicoy B, Fuster F, Cabezón M, Coll R, Ademà V, Grau J, Jiménez MJ, Pomares H, Marcé S, Mallo M, Millá F, Alonso E, Sureda A, Gallardo D, Feliu E, Ribera JM, Solé F, Zamora L.

Oncotarget. 2016 Aug 30;7(35):57021-57035. doi: 10.18632/oncotarget.10937.

18.

Reorganisation of Hoxd regulatory landscapes during the evolution of a snake-like body plan.

Guerreiro I, Gitto S, Novoa A, Codourey J, Nguyen Huynh TH, Gonzalez F, Milinkovitch MC, Mallo M, Duboule D.

Elife. 2016 Aug 1;5. pii: e16087. doi: 10.7554/eLife.16087.

19.

Oct4 Is a Key Regulator of Vertebrate Trunk Length Diversity.

Aires R, Jurberg AD, Leal F, Nóvoa A, Cohn MJ, Mallo M.

Dev Cell. 2016 Aug 8;38(3):262-74. doi: 10.1016/j.devcel.2016.06.021. Epub 2016 Jul 21.

20.

Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management.

Nicolle D, Fabre M, Simon-Coma M, Gorse A, Kappler R, Nonell L, Mallo M, Haidar H, Déas O, Mussini C, Guettier C, Redon MJ, Brugières L, Ghigna MR, Fadel E, Galmiche-Rolland L, Chardot C, Judde JG, Armengol C, Branchereau S, Cairo S.

Hepatology. 2016 Oct;64(4):1121-35. doi: 10.1002/hep.28621. Epub 2016 Jun 16.

PMID:
27115099
21.

Hoxb6 can interfere with somitogenesis in the posterior embryo through a mechanism independent of its rib-promoting activity.

Casaca A, Nóvoa A, Mallo M.

Development. 2016 Feb 1;143(3):437-48. doi: 10.1242/dev.133074. Epub 2015 Dec 30.

22.

Revisiting the involvement of signaling gradients in somitogenesis.

Mallo M.

FEBS J. 2016 Apr;283(8):1430-7. doi: 10.1111/febs.13622. Epub 2015 Dec 31. Review.

23.

Impact of SNP array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases.

Palomo L, Xicoy B, Garcia O, Mallo M, Ademà V, Cabezón M, Arnan M, Pomares H, José Larrayoz M, José Calasanz M, Maciejewski JP, Huang D, Shih LY, Ogawa S, Cervera J, Such E, Coll R, Grau J, Solé F, Zamora L.

Am J Hematol. 2016 Feb;91(2):185-92. doi: 10.1002/ajh.24227. Epub 2015 Dec 9.

24.

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.

McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF.

Oncotarget. 2015 Oct 27;6(33):34437-45. doi: 10.18632/oncotarget.5255.

25.

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.

McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF.

Blood Cancer J. 2015 Mar 13;5:e291. doi: 10.1038/bcj.2015.11.

26.

Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations.

Adema V, Larráyoz MJ, Calasanz MJ, Palomo L, Patiño-García A, Agirre X, Hernández-Rivas JM, Lumbreras E, Buño I, Martinez-Laperche C, Mallo M, García O, Álvarez S, Blazquez B, Cervera J, Luño E, Valiente A, Vallespí MT, Arenillas L, Collado R, Pérez-Oteyza J, Solé F.

Br J Haematol. 2015 Oct;171(1):137-41. doi: 10.1111/bjh.13355. Epub 2015 Feb 25. No abstract available.

PMID:
25716545
27.

Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.

Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Trümper L, Haase D, Schanz J.

Haematologica. 2015 Feb;100(2):205-13. doi: 10.3324/haematol.2014.110452. Epub 2014 Oct 24.

28.

Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL.

Cancer Cell. 2014 Oct 13;26(4):509-20. doi: 10.1016/j.ccr.2014.08.001. Epub 2014 Sep 18.

29.

Compartment-dependent activities of Wnt3a/β-catenin signaling during vertebrate axial extension.

Jurberg AD, Aires R, Nóvoa A, Rowland JE, Mallo M.

Dev Biol. 2014 Oct 15;394(2):253-63. doi: 10.1016/j.ydbio.2014.08.012. Epub 2014 Aug 23.

30.

Long bone development requires a threshold of Hox function.

González-Martín MC, Mallo M, Ros MA.

Dev Biol. 2014 Aug 15;392(2):454-65. doi: 10.1016/j.ydbio.2014.06.004. Epub 2014 Jun 12.

31.

Evolving locomotion with Hoxc9.

Mallo M.

Dev Cell. 2014 Apr 28;29(2):130-1. doi: 10.1016/j.devcel.2014.04.014.

32.

Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing.

Arenillas L, Mallo M, Ramos F, Guinta K, Barragán E, Lumbreras E, Larráyoz MJ, De Paz R, Tormo M, Abáigar M, Pedro C, Cervera J, Such E, José Calasanz M, Díez-Campelo M, Sanz GF, Hernández JM, Luño E, Saumell S, Maciejewski J, Florensa L, Solé F.

Genes Chromosomes Cancer. 2013 Dec;52(12):1167-77. doi: 10.1002/gcc.22112. Epub 2013 Oct 7.

PMID:
24123380
33.

The regulation of Hox gene expression during animal development.

Mallo M, Alonso CR.

Development. 2013 Oct;140(19):3951-63. doi: 10.1242/dev.068346. Review.

34.

5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.

Ortega M, Mallo M, Solé F, Sánchez-Morata C, López-Andreoni L, Martínez-Morgado N, Gironella M, Valcárcel D, Vallespí T.

Leuk Res. 2013 Oct;37(10):1248-50. doi: 10.1016/j.leukres.2013.06.021. Epub 2013 Jul 26.

PMID:
23891188
35.

Controlling Hox gene expression and activity to build the vertebrate axial skeleton.

Casaca A, Santos AC, Mallo M.

Dev Dyn. 2014 Jan;243(1):24-36. doi: 10.1002/dvdy.24007. Epub 2013 Jul 29. Review.

36.

Monosomal karyotype in MDS: explaining the poor prognosis?

Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Grau J, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D.

Leukemia. 2013 Oct;27(10):1988-95. doi: 10.1038/leu.2013.187. Epub 2013 Jun 21.

PMID:
23787396
37.

Switching axial progenitors from producing trunk to tail tissues in vertebrate embryos.

Jurberg AD, Aires R, Varela-Lasheras I, Nóvoa A, Mallo M.

Dev Cell. 2013 Jun 10;25(5):451-62. doi: 10.1016/j.devcel.2013.05.009.

38.

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.

Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G.

Am J Hematol. 2013 Oct;88(10):831-7. doi: 10.1002/ajh.23513. Epub 2013 Jul 23.

39.

Role of a polymorphism in a Hox/Pax-responsive enhancer in the evolution of the vertebrate spine.

Guerreiro I, Nunes A, Woltering JM, Casaca A, Nóvoa A, Vinagre T, Hunter ME, Duboule D, Mallo M.

Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10682-6. doi: 10.1073/pnas.1300592110. Epub 2013 May 14.

40.

Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

Mallo M, Del Rey M, Ibáñez M, Calasanz MJ, Arenillas L, Larráyoz MJ, Pedro C, Jerez A, Maciejewski J, Costa D, Nomdedeu M, Diez-Campelo M, Lumbreras E, González-Martínez T, Marugán I, Such E, Cervera J, Cigudosa JC, Alvarez S, Florensa L, Hernández JM, Solé F.

Br J Haematol. 2013 Jul;162(1):74-86. doi: 10.1111/bjh.12354. Epub 2013 Apr 25.

PMID:
23614682
41.

Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?

Ademà V, Hernández JM, Abáigar M, Lumbreras E, Such E, Calull A, Dominguez E, Arenillas L, Mallo M, Cervera J, Marugán I, Tormo M, García F, González T, Luño E, Sanzo C, Martín ML, Fernández M, Costa D, Blázquez B, Barreña B, Marco F, Batlle A, Buño I, Martínez-Laperche C, Noriega V, Collado R, Ivars D, Carbonell F, Vallcorba I, Melero J, Delgado E, Vargas MT, Grau J, Salido M, Espinet B, Melero C, Florensa L, Pedro C, Solé F.

Leuk Res. 2013 Apr;37(4):416-21. doi: 10.1016/j.leukres.2012.12.010. Epub 2013 Jan 18.

PMID:
23337401
42.

Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome.

Valcárcel D, Ademà V, Solé F, Ortega M, Nomdedeu B, Sanz G, Luño E, Cañizo C, de la Serna J, Ardanaz M, Marco V, Collado R, Grau J, Montoro J, Mallo M, Vallespí T.

J Clin Oncol. 2013 Mar 1;31(7):916-22. doi: 10.1200/JCO.2012.41.6073. Epub 2013 Jan 14.

PMID:
23319689
43.

Regulatory role for a conserved motif adjacent to the homeodomain of Hox10 proteins.

Guerreiro I, Casaca A, Nunes A, Monteiro S, Nóvoa A, Ferreira RB, Bom J, Mallo M.

Development. 2012 Aug;139(15):2703-10. doi: 10.1242/dev.081448. Epub 2012 Jun 21.

44.

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D.

J Clin Oncol. 2012 Mar 10;30(8):820-9. doi: 10.1200/JCO.2011.35.6394. Epub 2012 Feb 13.

45.

Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML).

Such E, Cervera J, Ibáñez M, Gómez-Seguí I, Luna I, López-Pavía M, Mallo M, Collado R, Vicente A, Hernández-Boluda JC, Luño E, Andreu R, Sanz GF, Sanz MA.

Leuk Res. 2012 Mar;36(3):e50-1. doi: 10.1016/j.leukres.2011.10.029. Epub 2011 Dec 5. No abstract available.

PMID:
22153185
46.

Concerted involvement of Cdx/Hox genes and Wnt signaling in morphogenesis of the caudal neural tube and cloacal derivatives from the posterior growth zone.

van de Ven C, Bialecka M, Neijts R, Young T, Rowland JE, Stringer EJ, Van Rooijen C, Meijlink F, Nóvoa A, Freund JN, Mallo M, Beck F, Deschamps J.

Development. 2011 Aug;138(16):3451-62. doi: 10.1242/dev.066118. Epub 2011 Jul 13. Erratum in: Development. 2011 Sep 1;138(17):3859.

47.

Deletion of TET2 gene in an acute myeloid leukemia case with a t(4;15)(q24;q26) characterized by glass needle based chromosome microdissection and oligonucleotide array.

Villa O, Mallo M, Kosyakova N, Salido M, Liehr T, Martínez-Avilés L, Pedro C, García-Aragonés M, Espinet B, Bellosillo B, Florensa L, Arenillas L, Cuscó I, Jurado LA, Solé F.

Leuk Res. 2011 Sep;35(9):e161-3. doi: 10.1016/j.leukres.2011.05.027. Epub 2011 Jun 17. No abstract available.

PMID:
21684005
48.

Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome.

Mallo M, Luño E, Sanzo C, Cervera J, Haase D, Schanz J, García-Manero G, del Cañizo C, Sanz GF, Solé F.

Leuk Res. 2011 Jun;35(6):834-6. doi: 10.1016/j.leukres.2011.01.003. Epub 2011 Jan 26.

PMID:
21269692
49.

Transient activation of meox1 is an early component of the gene regulatory network downstream of hoxa2.

Kirilenko P, He G, Mankoo BS, Mallo M, Jones R, Bobola N.

Mol Cell Biol. 2011 Mar;31(6):1301-8. doi: 10.1128/MCB.00705-10. Epub 2011 Jan 18.

50.

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

Such E, Cervera J, Costa D, Solé F, Vallespí T, Luño E, Collado R, Calasanz MJ, Hernández-Rivas JM, Cigudosa JC, Nomdedeu B, Mallo M, Carbonell F, Bueno J, Ardanaz MT, Ramos F, Tormo M, Sancho-Tello R, del Cañizo C, Gómez V, Marco V, Xicoy B, Bonanad S, Pedro C, Bernal T, Sanz GF.

Haematologica. 2011 Mar;96(3):375-83. doi: 10.3324/haematol.2010.030957. Epub 2010 Nov 25.

Supplemental Content

Support Center